MCID: LYM051
MIFTS: 50

Lymphomatoid Granulomatosis

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Lymphomatoid Granulomatosis

MalaCards integrated aliases for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 38 76 53 59 55 73
Granulomatosis, Lymphomatoid 76
Lyg 59

Characteristics:

Orphanet epidemiological data:

59
lymphomatoid granulomatosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA86869
ICD10 via Orphanet 34 C83.8
MESH via Orphanet 45 D008230
UMLS via Orphanet 74 C0024307
UMLS 73 C0024307

Summaries for Lymphomatoid Granulomatosis

NIH Rare Diseases : 53 Lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as B lymphocytes. These B cells can build up in the tissues of the body, causing damage to the blood vessels. In many cases of lymphomatoid granulomatosis, the abnormal B cells contain the Epstein-Barr virus. The disease is more common in men, usually after the fifth decade of life. Lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. Signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. Skin lesions and central nervous system changes such as headaches, seizures, and ataxia may also be seen. Rarely, the disorder can affect the kidneys or liver. The cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part. Treatment depends on the extent of the disease but may include interferon alfa-2b and combination chemotherapy with rituximab. Occasionally, the disorder resolves on its own without treatment. There has been some debate as to whether lymphomatoid granulomatosis should be viewed as a as a B-cell lymphoma or a lymphoproliferative disease or whether it should be viewed merely as a condition that can develop into a B-cell lymphoma. The prognosis is variable, though lymphomatoid granulomatosis can progress and become fatal in some cases. 

MalaCards based summary : Lymphomatoid Granulomatosis, also known as granulomatosis, lymphomatoid, is related to lymphomatoid papulosis and lymphoma, hodgkin, classic, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Allograft rejection. The drugs Ketamine and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include b cells, lung and bone.

Wikipedia : 76 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Related Diseases for Lymphomatoid Granulomatosis

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 lymphomatoid papulosis 29.7 GZMB TIA1
2 lymphoma, hodgkin, classic 29.5 GZMB TIA1
3 myelofibrosis 28.2 IFNA1 IFNA2
4 lymphoproliferative syndrome 1 11.3
5 lymphoproliferative syndrome, x-linked, 1 11.2
6 lymphoma 10.5
7 cerebritis 10.3
8 arthritis 10.3
9 leukemia 10.2
10 rheumatoid arthritis 10.2
11 autoimmune lymphoproliferative syndrome, type v 10.2
12 acquired immunodeficiency syndrome 10.2
13 lymphosarcoma 10.2
14 orbit lymphoma 10.1 GZMB TIA1
15 pneumonia 10.1
16 vasculitis 10.1
17 polymorphic reticulosis 10.1
18 lichen sclerosus et atrophicus 10.1 GZMB TIA1
19 viral esophagitis 10.1 GZMB TIA1
20 lymphocytic gastritis 10.1 GZMB TIA1
21 subcutaneous panniculitis-like t-cell lymphoma 10.0 GZMB TIA1
22 primary cutaneous anaplastic large cell lymphoma 10.0 GZMB TIA1
23 natural killer cell leukemia 10.0 GZMB TIA1
24 composite lymphoma 10.0 GZMB TIA1
25 alopecia areata 10.0 CXCL9 GZMB
26 hepatosplenic t-cell lymphoma 10.0 GZMB TIA1
27 choriocarcinoma of the testis 10.0 GZMB TIA1
28 b-cell lymphomas 10.0
29 hematopoietic stem cell transplantation 10.0
30 lymphoblastic leukemia 10.0
31 neuropathy 10.0
32 lethal midline granuloma 10.0
33 giardiasis 10.0 GZMB TIA1
34 infiltrating lipoma 10.0 GZMB TIA1
35 necrotizing sialometaplasia 10.0 GZMB TIA1
36 lichen planus 10.0 CXCL9 GZMB
37 panniculitis 10.0 GZMB TIA1
38 reticulosarcoma 10.0 GZMB TIA1
39 b-cell expansion with nfkb and t-cell anergy 9.9 GZMB TIA1
40 wiskott-aldrich syndrome 9.9
41 wegener granulomatosis 9.9
42 leukemia, acute lymphoblastic 9.9
43 cervicitis 9.9
44 mediastinitis 9.9
45 lung disease 9.9
46 large granular lymphocyte leukemia 9.9
47 squamous papillomatosis 9.9 IFNA1 IFNA2
48 cryoglobulinemia, familial mixed 9.9 IFNA1 IFNA2
49 peripheral t-cell lymphoma 9.9 GZMB TIA1
50 chronic neutrophilic leukemia 9.8 IFNA1 IFNA2

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:



Diseases related to Lymphomatoid Granulomatosis

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

UMLS symptoms related to Lymphomatoid Granulomatosis:


fever, malaise

Drugs & Therapeutics for Lymphomatoid Granulomatosis

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
3
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
6
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
7
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
8 Orange Approved, Nutraceutical Phase 3
9
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
10
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable
13 Anesthetics Phase 3
14 Anesthetics, Dissociative Phase 3
15 Anesthetics, General Phase 3
16 Anesthetics, Intravenous Phase 3
17 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
18 Excitatory Amino Acid Antagonists Phase 3
19 Excitatory Amino Acids Phase 3
20 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Amoxicillin-Potassium Clavulanate Combination Phase 3
23 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Antitubercular Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 beta-Lactamase Inhibitors Phase 3
28 Clavulanic Acid Phase 3
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Analgesics, Opioid Phase 3,Not Applicable
33 Narcotics Phase 3,Not Applicable
34 Adjuvants, Anesthesia Phase 3
35 Liver Extracts Phase 3,Phase 1,Phase 2
36 Antimitotic Agents Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Ferric Compounds Phase 3
39 ferric gluconate Phase 3
40 Hematinics Phase 3,Phase 2
41 Cola Nutraceutical Phase 3,Phase 1,Phase 2
42 Iron Supplement Nutraceutical Phase 3
43
rituximab Approved Phase 1, Phase 2,Phase 2,Not Applicable 174722-31-7 10201696
44
Busulfan Approved, Investigational Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
45
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
46
Fludarabine Approved Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
47
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 2,Phase 1,Not Applicable 24280-93-1 446541
50
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 179)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
10 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
11 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
12 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
13 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
14 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
15 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
16 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
17 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
18 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
19 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
20 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
21 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
22 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
23 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
24 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
25 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
26 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
27 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
28 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
29 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
30 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
31 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
33 Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
34 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
35 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed NCT00365768 Phase 2 Glutamine
36 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Completed NCT00238433 Phase 2 busulfan;melphalan;thiotepa
37 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
38 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
39 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
40 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
41 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2 Rituxan and EPOCH
42 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
43 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
44 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
45 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
46 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
47 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
48 Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT00612716 Phase 2 busulfan;cyclophosphamide
49 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
50 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.

Genetic Tests for Lymphomatoid Granulomatosis

Anatomical Context for Lymphomatoid Granulomatosis

MalaCards organs/tissues related to Lymphomatoid Granulomatosis:

41
B Cells, Lung, Bone, Liver, T Cells, Kidney, Bone Marrow

Publications for Lymphomatoid Granulomatosis

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 423)
# Title Authors Year
1
Oral Manifestation of Lymphomatoid Granulomatosis. ( 29542064 )
2018
2
Lymphomatoid Granulomatosis in a 14-Year-Old Boy with Trisomy 21 and History of B-Lymphoblastic Leukemia/Lymphoma. ( 29336635 )
2018
3
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. ( 29473430 )
2018
4
Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. ( 29635846 )
2018
5
Pulmonary lymphomatoid granulomatosis diagnosed by image-guided core needle biopsy. ( 29020803 )
2018
6
Lymphomatoid Granulomatosis with Isolated Cutaneous lesions : Prolonged remission after" DAEPOCH" protocol. ( 29856361 )
2018
7
The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis: A Case Report and Literature Review. ( 29877270 )
2018
8
Cartilage hair hypoplasia with cutaneous lymphomatoid granulomatosis. ( 29744913 )
2018
9
Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report. ( 29739366 )
2018
10
Pitfall of <sup>18</sup>F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. ( 29884684 )
2018
11
Lymphomatoid granulomatosis: A case series from South India. ( 29676363 )
2018
12
Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis. ( 28838746 )
2017
13
Cutaneous human immunodeficiency virus (HIV)-associated lymphomatoid granulomatosis: complete regression following antiretroviral therapy. ( 28188620 )
2017
14
The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature. ( 28824078 )
2017
15
Rare case of pulmonary lymphomatoid granulomatosis in conjunction with tuberculosis: A case report. ( 29049243 )
2017
16
A Case of Hodgkin Lymphoma Mimicking Lymphomatoid Granulomatosis Diagnosed at Autopsy. ( 29165611 )
2017
17
A Rare Case of Pulmonary Lymphomatoid Granulomatosis. ( 28810098 )
2017
18
Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement. ( 28167690 )
2017
19
Unsuspected lymphomatoid granulomatosis in a patient with antisynthetase syndrome. ( 29136066 )
2017
20
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. ( 28293550 )
2017
21
Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. ( 27521314 )
2016
22
Lymphomatoid granulomatosis - A rare pulmonary lymphoproliferative disease. ( 26898887 )
2016
23
Lymphomatoid Granulomatosis: Two Different Phenotypes of Computed Tomography Findings. ( 27768635 )
2016
24
Lymphomatoid granulomatosis of the brain: A case report. ( 27656321 )
2016
25
Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. ( 27671987 )
2016
26
Lymphomatoid Granulomatosis with Paraneoplastic Polymyositis: A Rare Malignancy with Rare Complication. ( 26966605 )
2016
27
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other. ( 27454071 )
2016
28
Lymphomatoid granulomatosis initially presenting as ulcerated subcutaneous and muscle lesions without pulmonary involvement. ( 27988929 )
2016
29
Pulmonary Lymphomatoid Granulomatosis- a Case Report with Review of Literature. ( 27872542 )
2016
30
Lymphomatoid granulomatosis coronary vasculitis and cardiomyopathy: Depiction of extent and severity on cardiac CT. ( 27021253 )
2016
31
Primary Orbital Lymphomatoid Granulomatosis in a 1-Year-Old Child. ( 26692728 )
2015
32
Granulomatous Lymphoproliferative Disorders: Granulomatous Slack Skin and Lymphomatoid Granulomatosis. ( 26143428 )
2015
33
A case of lymphomatoid granulomatosis presenting with cutaneous lesions. ( 27051739 )
2015
34
Fever, Dry Cough and Exertional Dyspnea: Pulmonary Lymphomatoid Granulomatosis Masquerading as Pneumonia, Granulomatosis with Polyangiitis and Infectious Mononucleosis. ( 26631890 )
2015
35
Lymphomatoid granulomatosis mimicking vasculitis. ( 26382276 )
2015
36
Pathology in Practice. Lymphomatoid granulomatosis of lung tissue and mediastinal lymph node in a dog. ( 26517613 )
2015
37
Clinical, imaging and histopathological features of isolated CNS lymphomatoid granulomatosis. ( 25709167 )
2015
38
Lymphomatoid Granulomatosis. ( 26386275 )
2015
39
Pulmonary lymphomatoid granulomatosis. A rare entity in the differential diagnosis of pulmonary nodules. ( 26078192 )
2015
40
Biopsy-proven muscular involvement of lymphomatoid granulomatosis assessed by (18)FDG-PET Scan. ( 25623523 )
2015
41
Primary cerebral lymphomatoid granulomatosis progressing to methotrexate-associated lymphoproliferative disease under immunosuppressive therapy. ( 25758078 )
2015
42
Lymphomatoid Granulomatosis with Central Nervous System Involvement Successfully Treated with Cyclophosphamide, High-dose Cytarabine, Dexamethasone, Etoposide, and Rituximab (CHASER therapy) Followed by Brain Irradiation: A Case Study. ( 26096049 )
2015
43
Epstein-Barr virus-driven B Cell Proliferation with CD4(+) T Cell Expansion: A Lymphomatoid Granulomatosis-like Disease Related to Hyperinterleukin-10 Secretion of Remarkably Favourable Outcome with Rituximab. ( 26332210 )
2015
44
Paediatric grade-II lymphomatoid granulomatosis: (18)F-FDG PET/CT monitoring of disease activity. ( 26522001 )
2015
45
Pulmonary manifestation of lymphomatoid granulomatosis. ( 26071366 )
2015
46
Low grade pulmonary lymphomatoid granulomatosis with an endobronchial mass. ( 25861350 )
2015
47
Lymphomatoid Granulomatosis-A Single Institute Experience: Pathologic Findings and Clinical Correlations. ( 25321327 )
2014
48
Lymphomatoid granulomatosis of central nervous system and lung driven by epstein barr virus proliferation: successful treatment with rituximab-containing chemotherapy. ( 24678394 )
2014
49
Fatal lymphomatoid granulomatosis with primary CNS-involvement in an immunocompetent 80-year-old woman. ( 25535225 )
2014
50
Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. ( 25130128 )
2014

Variations for Lymphomatoid Granulomatosis

Expression for Lymphomatoid Granulomatosis

Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.

Pathways for Lymphomatoid Granulomatosis

GO Terms for Lymphomatoid Granulomatosis

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.7 GZMB IFNA2 TIA1
2 regulation of signaling receptor activity GO:0010469 9.65 CXCL9 IFNA1 IFNA2
3 B cell differentiation GO:0030183 9.51 IFNA1 IFNA2
4 type I interferon signaling pathway GO:0060337 9.49 IFNA1 IFNA2
5 humoral immune response GO:0006959 9.46 IFNA1 IFNA2
6 response to exogenous dsRNA GO:0043330 9.43 IFNA1 IFNA2
7 B cell proliferation GO:0042100 9.4 IFNA1 IFNA2
8 regulation of type I interferon-mediated signaling pathway GO:0060338 9.37 IFNA1 IFNA2
9 T cell activation involved in immune response GO:0002286 9.32 IFNA1 IFNA2
10 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA1 IFNA2
11 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA1 IFNA2
12 defense response to virus GO:0051607 9.13 CXCL9 IFNA1 IFNA2
13 defense response GO:0006952 8.8 CXCL9 IFNA1 IFNA2

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 cytokine activity GO:0005125 9.13 CXCL9 IFNA1 IFNA2
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2

Sources for Lymphomatoid Granulomatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....